Dermatomyositis, Antisynthetase-Syndrom und immunvermittelte nekrotisierende Myopathie

Zusammenfassung

Die inflammatorischen Myopathien werden heutzutage anhand von Klinik, Biopsie und Antikörperstatus genauer gegliedert. Zumeist sind sowohl die Dermatomyositis, das Antisynthetase-Syndrom (ASyS) und die Immunvermittelte nekrotisierende Myopathie (IMNM) durch proximale Muskelschwäche gekennzeichnet, wobei jedoch einige Entitäten auch amyopathisch verlaufen können. Je nach vorliegender Antikörperart kann die Dermatomyositis jeweils unterschiedliche Manifestationen aufweisen, wobei die interstitielle Lungenerkrankung (ILD) als häufigste extramuskuläre Beteiligung zu erwähnen ist. Ein besonderes Augenmerk sollte auf das Tumorscreening bei Vorliegen entsprechender Risikofaktoren, wie beispielsweise bei anti-TIF1γ oder anti-NXP2-positivem Antikörperstatus bei Erwachsenen, gelegt werden. Die IMNMs sind bekanntermaßen mit einer Statinexposition assoziiert, allerdings sollte bedacht werden, dass eine Statinexposition nicht zwingend nötig ist, um eine IMNM zu entwickeln. Das ASyS präsentiert sich regulär mit einer Triade aus Myositis, Arthritis und ILD, welche jedoch nicht immer vorliegen muss. Therapeutisch unterscheiden sich die drei Gruppen initial nicht. Eine überbrückende Prednisolontherapie (je nach Schweregrad oral oder intravenös) wird initiiert und je nach Grunderkrankung und Organbeteiligung parallel eine steroidsparende Erhaltungstherapie etabliert. Eine ergänzende Physiotherapie sowie bei Bedarf auch Ergo- oder Logopädie sind wichtige Bausteine der Therapie und sollten frühzeitig begonnen werden.

Abstract

Today, idiopathic inflammatory myopathies are categorised more precisely based on clinical findings, histopathological aspects, and autoantibody status, e. g., into dermatomyositis, antisynthetase syndrome, and immune-mediated necrotising myopathy (IMNM). These mostly present with proximal muscle weakness, although the disease can also occur in an amyopathic form in some cases. Dermatomyositis patients may present with varying manifestations, depending on the antibody status, with interstitial lung disease (ILD) being the most common extramuscular presentation. Especially in the presence of concomitant risk factors such as anti-TIF1γ or anti-NXP2-positive antibodies, a tumour screening should be performed in adult patients. IMNMs are known as being associated with exposure to statins, but it should be borne in mind that statin exposure is not a precondition for the development of an IMNM. Antisynthetase syndrome usually presents with a triad of myositis, arthritis, and ILD. Here, too, the classical triad is not necessarily present. As regards therapeutic approaches, the three entities do not initially differ. An initial steroid therapy is started and complemented by steroid-sparing maintenance therapy, which depends on the severity and organ involvement of the disease. Physiotherapy and, if needed, occupational therapy and logopaedics are integral parts of the treatment and should be initiated at an early point in time.

Schlüsselwörter

Dermatomyositis - Antisynthetase-Syndrom - Immunvermittelte nekrotisierende Myopathie - Autoantikörper - Idiopathisch inflammatorische Myopathie

Keywords

dermatomyositis - antisynthetase syndrome - autoantibody - idiopathic inflammatory myopathy - immune-mediated necrotising myopathy

Publication History

Article published online:
26 June 2024

• Literatur

• 1 Lundberg IE, Tjärnlund A, Bottai M. et al. EULAR/ACR Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and their Major Subgroups. Arthritis Rheumatol 2017; 69: 2271-2282 DOI: 10.1002/art.40320.
• 2 Casal-Dominguez M, Pinal-Fernandez I, Pak K. et al. Performance of the 2017 EULAR/ACR classification criteria for inflammatory myopathies in patients with myositis-specific autoantibodies. Arthritis Rheumatol 2022; 74: 508-517 DOI: 10.1002/art.41964.
• 3 van der Meulen MFG, Bronner IM, Hoogendijk JE. et al. Polymyositis: an overdiagnosed entity. Neurology 2003; 61: 316-321 DOI: 10.1212/wnl.61.3.316.
• 4 Amato AA, Griggs RC. Unicorns, dragons, polymyositis, and other mythological beasts. Neurology 2003; 61: 288-289 DOI: 10.1212/wnl.61.3.288.
• 5 Betteridge Z, McHugh N. Myositis-specific autoantibodies: an important tool to support diagnosis of myositis. J Intern Med 2016; 280: 8-23 DOI: 10.1111/joim.12451.
• 6 Wiendl H, Schmidt J. S2k-Leitlinie Myositissyndrome (28.04.2022). Im Internet: https://register.awmf.org/de/leitlinien/detail/030-054; Stand: am 06.01.2024
• 7 Lundberg IE, Fujimoto M, Vencovsky J. et al. Idiopathic inflammatory myopathies. Nat Rev Dis Primers 2021; 7: 86 DOI: 10.1038/s41572-021-00321-x.
• 8 McHugh NJ, Tansley SL. Autoantibodies in myositis. Nat Rev Rheumatol 2018; 14: 290-302 DOI: 10.1038/nrrheum.2018.56.
• 9 Janda V. Manuelle Muskelfunktionsdiagnostik. 4. Aufl. München, Jena: Urban und Fischer; 2000
• 10 Rider LG, Werth VP, Huber AM. et al. Measures for Adult and Juvenile Dermatomyositis, Polymyositis, and Inclusion Body Myositis. Arthritis Care Res (Hoboken) 2011; 63: S118-S157 DOI: 10.1002/acr.20532.
• 11 Labeit B, Pawlitzki M, Ruck T. et al. The Impact of Dysphagia in Myositis: A Systematic Review and Meta-Analysis. J Clin Med 2020; 9 DOI: 10.3390/jcm9072150.
• 12 Hallowell RW, Danoff SK. Diagnosis and Management of Myositis-Associated Lung Disease. Chest 2023; 163: 1476-1491 DOI: 10.1016/j.chest.2023.01.031.
• 13 Schmidt J, Müller-Felber W. Myositis: von der Diagnose zur Therapie. Nervenarzt 2023; 94: 510-518 DOI: 10.1007/s00115-023-01490-8.
• 14 Xie H, Zhang D, Wang Y. et al. Risk factors for mortality in patients with anti-MDA5 antibody-positive dermatomyositis: A meta-analysis and systematic review. Semin Arthritis Rheum 2023; 62: 152231 DOI: 10.1016/j.semarthrit.2023.152231.
• 15 Lu X, Peng Q, Wang G. Anti-MDA5 antibody-positive dermatomyositis: pathogenesis and clinical progress. Nat Rev Rheumatol 2024; 20: 48-62 DOI: 10.1038/s41584-023-01054-9.
• 16 Graf M, von Stuckrad SL, Uruha A. et al. SIGLEC1 enables straightforward assessment of type I interferon activity in idiopathic inflammatory myopathies. RMD Open 2022; 8 DOI: 10.1136/rmdopen-2021-001934.
• 17 Gono T, Kawaguchi Y, Sugiura T. et al. Interleukin-18 is a key mediator in dermatomyositis: potential contribution to development of interstitial lung disease. Rheumatology (Oxford) 2010; 49: 1878-1881 DOI: 10.1093/rheumatology/keq196.
• 18 Damoiseaux J, Mammen AL, Piette Y. et al. 256th ENMC international workshop: Myositis specific and associated autoantibodies (MSA-ab): Amsterdam, The Netherlands, 8-10 October 2021. Neuromuscul Disord 2022; 32: 594-608 DOI: 10.1016/j.nmd.2022.05.011.
• 19 Mecoli CA, Albayda J, Tiniakou E. et al. Myositis Autoantibodies: A Comparison of Results From the Oklahoma Medical Research Foundation Myositis Panel to the Euroimmun Research Line Blot. Arthritis Rheumatol 2020; 72: 192-194 DOI: 10.1002/art.41088.
• 20 Liang L, Zhang Y-M, Chen H. et al. Anti-Mi-2 antibodies characterize a distinct clinical subset of dermatomyositis with favourable prognosis. Eur J Dermatol 2020; DOI: 10.1684/ejd.2020.3750.
• 21 Allenbach Y, Mammen AL, Benveniste O. et al. 224th ENMC International Workshop: Clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14-16 October 2016. Neuromuscul Disord 2018; 28: 87-99 DOI: 10.1016/j.nmd.2017.09.016.
• 22 Meyer A, Sibilia J. Strategy for suspected myositis. Joint Bone Spine 2019; 86: 568-575 DOI: 10.1016/j.jbspin.2019.01.013.
• 23 Merve A, Schneider U, Kara E. et al. Muscle biopsy in myositis: What the rheumatologist needs to know. Best Pract Res Clin Rheumatol 2022; 36: 101763 DOI: 10.1016/j.berh.2022.101763.
• 24 Ruffer N, Krusche M, Stenzel W. et al. Comment on: Rescue therapy of antisynthetase syndrome with CD19-targeted CAR-T cells after failure of several B-cell depleting antibodies. Rheumatology (Oxford) 2023; DOI: 10.1093/rheumatology/kead668.
• 25 Huang K, Aggarwal R. Antisynthetase syndrome: A distinct disease spectrum. J Scleroderma Relat Disord 2020; 5: 178-191 DOI: 10.1177/2397198320902667.
• 26 DeWane ME, Waldman R, Lu J. Dermatomyositis: Clinical features and pathogenesis. J Am Acad Dermatol 2020; 82: 267-281 DOI: 10.1016/j.jaad.2019.06.1309.
• 27 Allenbach Y, Uzunhan Y, Toquet S. et al. Different phenotypes in dermatomyositis associated with anti-MDA5 antibody: Study of 121 cases. Neurology 2020; 95: e70-e78 DOI: 10.1212/WNL.0000000000009727.
• 28 Xu A, Ye Y, Fu Q. et al. Prognostic values of anti-Ro52 antibodies in anti-MDA5-positive clinically amyopathic dermatomyositis associated with interstitial lung disease. Rheumatology (Oxford) 2021; 60: 3343-3351 DOI: 10.1093/rheumatology/keaa786.
• 29 Yan T-T, Zhang X, Yang H-H. et al. Association of anti-NXP2 antibody with clinical characteristics and outcomes in adult dermatomyositis: results from clinical applications based on a myositis-specific antibody. Clin Rheumatol 2021; 40: 3695-3702 DOI: 10.1007/s10067-021-05667-x.
• 30 Mammen AL, Allenbach Y, Stenzel W. et al. 239^th ENMC International Workshop: Classification of dermatomyositis, Amsterdam, the Netherlands, 14-16 December 2018. Neuromuscul Disord 2020; 30: 70-92 DOI: 10.1016/j.nmd.2019.10.005.
• 31 Kissel JT, Mendell JR, Rammohan KW. Microvascular deposition of complement membrane attack complex in dermatomyositis. N Engl J Med 1986; 314: 329-334 DOI: 10.1056/NEJM198602063140601.
• 32 Zhou D, King EH, Rothwell S. et al. Low copy numbers of complement C4 and C4A deficiency are risk factors for myositis, its subgroups and autoantibodies. Ann Rheum Dis 2023; 82: 235-245 DOI: 10.1136/ard-2022-222935.
• 33 Greenberg SA, Pinkus JL, Pinkus GS. et al. Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol 2005; 57: 664-678 DOI: 10.1002/ana.20464.
• 34 Walsh RJ, Kong SW, Yao Y. et al. Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis. Arthritis Rheum 2007; 56: 3784-3792 DOI: 10.1002/art.22928.
• 35 Pinal-Fernandez I, Casal-Dominguez M, Derfoul A. et al. Identification of distinctive interferon gene signatures in different types of myositis. Neurology 2019; 93: e1193-e1204 DOI: 10.1212/WNL.0000000000008128.
• 36 Qian J, Xu H. COVID-19 Disease and Dermatomyositis: A Mini-Review. Front Immunol 2021; 12: 747116 DOI: 10.3389/fimmu.2021.747116.
• 37 Oldroyd AGS, Callen JP, Chinoy H. et al. International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening: an International Myositis Assessment and Clinical Studies Group (IMACS) initiative. Nat Rev Rheumatol 2023; 19: 805-817 DOI: 10.1038/s41584-023-01045-w.
• 38 Best M, Molinari N, Chasset F. et al. Use of Anti-transcriptional Intermediary Factor-1 Gamma Autoantibody in Identifying Adult Dermatomyositis Patients with Cancer: A Systematic Review and Meta-analysis. Acta Derm Venereol 2019; 99: 256-262 DOI: 10.2340/00015555-3091.
• 39 Aussy A, Fréret M, Gallay L. et al. The IgG2 Isotype of Anti-Transcription Intermediary Factor 1γ Autoantibodies Is a Biomarker of Cancer and Mortality in Adult Dermatomyositis. Arthritis Rheumatol 2019; 71: 1360-1370 DOI: 10.1002/art.40895.
• 40 Fiorentino DF, Mecoli CA, Rosen MC. et al. Immune responses to CCAR1 and other dermatomyositis autoantigens are associated with attenuated cancer emergence. J Clin Invest 2022; 132 DOI: 10.1172/JCI150201.
• 41 Hida A, Yamashita T, Hosono Y. et al. Anti-TIF1-γ antibody and cancer-associated myositis: A clinicohistopathologic study. Neurology 2016; 87: 299-308 DOI: 10.1212/WNL.0000000000002863.
• 42 Tanboon J, Inoue M, Hirakawa S. et al. Pathologic Features of Anti-Mi-2 Dermatomyositis. Neurology 2021; 96: e448-e459 DOI: 10.1212/WNL.0000000000011269.
• 43 Ichimura Y, Konishi R, Shobo M. et al. Anti-nuclear matrix protein 2 antibody-positive inflammatory myopathies represent extensive myositis without dermatomyositis-specific rash. Rheumatology (Oxford) 2022; 61: 1222-1227 DOI: 10.1093/rheumatology/keab518.
• 44 Albayda J, Pinal-Fernandez I, Huang W. et al. Antinuclear Matrix Protein 2 Autoantibodies and Edema, Muscle Disease, and Malignancy Risk in Dermatomyositis Patients. Arthritis Care Res (Hoboken) 2017; 69: 1771-1776 DOI: 10.1002/acr.23188.
• 45 Ge Y, Lu X, Shu X. et al. Clinical characteristics of anti-SAE antibodies in Chinese patients with dermatomyositis in comparison with different patient cohorts. Sci Rep 2017; 7: 188 DOI: 10.1038/s41598-017-00240-6.
• 46 Bernet LL, Lewis MA, Rieger KE. et al. Ovoid Palatal Patch in Dermatomyositis: A Novel Finding Associated With Anti-TIF1γ (p155) Antibodies. JAMA Dermatol 2016; 152: 1049-1051 DOI: 10.1001/jamadermatol.2016.1429.
• 47 Nishikai M, Reichlin M. Heterogeneity of precipitating antibodies in polymyositis and dermatomyositis. Characterization of the Jo-1 antibody system. Arthritis Rheum 1980; 23: 881-888 DOI: 10.1002/art.1780230802.
• 48 Marguerie C, Bunn CC, Beynon HL. et al. Polymyositis, pulmonary fibrosis and autoantibodies to aminoacyl-tRNA synthetase enzymes. Q J Med 1990; 77: 1019-1038 DOI: 10.1093/qjmed/77.1.1019.
• 49 Sasai T, Nakashima R, Shirakashi M. et al. A new autoantibody to valyl transfer RNA synthetase associated with anti-synthetase syndrome. Rheumatology (Oxford) 2023; 62: e155-e157 DOI: 10.1093/rheumatology/keac569.
• 50 Vulsteke J-B, Derua R, Dubucquoi S. et al. Mass spectrometry-based identification of new anti-Ly and known antisynthetase autoantibodies. Ann Rheum Dis 2023; 82: 546-555 DOI: 10.1136/ard-2022-222686.
• 51 Preger C, Notarnicola A, Hellström C. et al. Autoantigenic properties of the aminoacyl tRNA synthetase family in idiopathic inflammatory myopathies. J Autoimmun 2023; 134: 102951 DOI: 10.1016/j.jaut.2022.102951.
• 52 Arcani R, Rey L, Mazziotto A. et al. Anti-Jo-1 autoantibodies: biomarkers of severity and evolution of the disease in antisynthetase syndrome. Arthritis Res Ther 2023; 25 DOI: 10.1186/s13075-023-03116-5.
• 53 Bozzalla-Cassione E, Zanframundo G, Biglia A. et al. Anti-Ro52 antibodies positivity in antisynthetase syndrome: a single centre cohort study. Clin Exp Rheumatol 2022; 40: 27-31 DOI: 10.55563/clinexprheumatol/bjb2gf.
• 54 Leclair V, Notarnicola A, Vencovsky J. et al. Polymyositis: does it really exist as a distinct clinical subset?. Curr Opin Rheumatol 2021; 33: 537-543 DOI: 10.1097/BOR.0000000000000837.
• 55 Zanframundo G, Faghihi-Kashani S, Scirè CA. et al. Defining anti-synthetase syndrome: a systematic literature review. Clin Exp Rheumatol 2022; 40: 309-319 DOI: 10.55563/clinexprheumatol/8xj0b9.
• 56 Hum RM, Lilleker JB, Lamb JA. et al. Comparison of clinical features between patients with anti-synthetase syndrome and dermatomyositis: Results from the MYONET registry. Rheumatology (Oxford) 2023; DOI: 10.1093/rheumatology/kead481.
• 57 Hervier B, Meyer A, Dieval C. et al. Pulmonary hypertension in antisynthetase syndrome: prevalence, aetiology and survival. Eur Respir J 2013; 42: 1271-1282 DOI: 10.1183/09031936.00156312.
• 58 Dieval C, Deligny C, Meyer A. et al. Myocarditis in Patients With Antisynthetase Syndrome: Prevalence, Presentation, and Outcomes. Medicine (Baltimore) 2015; 94: e798 DOI: 10.1097/MD.0000000000000798.
• 59 Cavagna L, Trallero-Araguás E, Meloni F. et al. Influence of Antisynthetase Antibodies Specificities on Antisynthetase Syndrome Clinical Spectrum Time Course. J Clin Med 2019; 8 DOI: 10.3390/jcm8112013.
• 60 Weiss M, Holzer MT, Muehlensiepen F. et al. Healthcare utilization and unmet needs of patients with antisynthetase syndrome: An international patient survey. Rheumatol Int 2023; 43: 1925-1934 DOI: 10.1007/s00296-023-05372-9.
• 61 Aggarwal R, Cassidy E, Fertig N. et al. Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients. Ann Rheum Dis 2014; 73: 227-232 DOI: 10.1136/annrheumdis-2012-201800.
• 62 Hervier B, Devilliers H, Stanciu R. et al. Hierarchical cluster and survival analyses of antisynthetase syndrome: phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity. Autoimmun Rev 2012; 12: 210-217 DOI: 10.1016/j.autrev.2012.06.006.
• 63 Tang HS, Tang IYK, Ho RTC. et al. Clinical heterogeneity and prognostic factors of anti-synthetase syndrome: a multi-centered retrospective cohort study. Rheumatology (Oxford) 2023; DOI: 10.1093/rheumatology/kead671.
• 64 Stenzel W, Preuße C, Allenbach Y. et al. Nuclear actin aggregation is a hallmark of anti-synthetase syndrome-induced dysimmune myopathy. Neurology 2015; 84: 1346-1354 DOI: 10.1212/WNL.0000000000001422.
• 65 Preuße C, Paesler B, Nelke C. et al. Skeletal muscle provides the immunological micro-milieu for specific plasma cells in anti-synthetase syndrome-associated myositis. Acta Neuropathol 2022; 144: 353-372 DOI: 10.1007/s00401-022-02438-z.
• 66 Holzer M-T, Ruffer N, Huber TB. et al. Daratumumab for autoimmune diseases: a systematic review. RMD Open 2023; 9 DOI: 10.1136/rmdopen-2023-003604.
• 67 Benveniste O, Drouot L, Jouen F. et al. Correlation of anti-signal recognition particle autoantibody levels with creatine kinase activity in patients with necrotizing myopathy. Arthritis Rheum 2011; 63: 1961-1971 DOI: 10.1002/art.30344.
• 68 Werner JL, Christopher-Stine L, Ghazarian SR. et al. Antibody levels correlate with creatine kinase levels and strength in anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Arthritis Rheum 2012; 64: 4087-4093 DOI: 10.1002/art.34673.
• 69 Bergua C, Chiavelli H, Allenbach Y. et al. In vivo pathogenicity of IgG from patients with anti-SRP or anti-HMGCR autoantibodies in immune-mediated necrotising myopathy. Ann Rheum Dis 2019; 78: 131-139 DOI: 10.1136/annrheumdis-2018-213518.
• 70 Khoo T, Chinoy H. Anti-HMGCR immune-mediated necrotising myopathy: Addressing the remaining issues. Autoimmun Rev 2023; 22: 103468 DOI: 10.1016/j.autrev.2023.103468.
• 71 Szczesny P, Barsotti S, Nennesmo I. et al. Screening for Anti-HMGCR Antibodies in a Large Single Myositis Center Reveals Infrequent Exposure to Statins and Diversiform Presentation of the Disease. Front Immunol 2022; 13: 866701 DOI: 10.3389/fimmu.2022.866701.
• 72 Dallevet C-A, Benveniste O, Allenbach Y. Pathogenesis and Treatment in IMNM. Curr Treatm Opt Rheumatol 2023; 9: 32-48 DOI: 10.1007/s40674-023-00201-3.
• 73 Allenbach Y, Benveniste O, Stenzel W. et al. Immune-mediated necrotizing myopathy: clinical features and pathogenesis. Nat Rev Rheumatol 2020; 16: 689-701 DOI: 10.1038/s41584-020-00515-9.
• 74 Kleefeld F, Uruha A, Schänzer A. et al. Morphologic and Molecular Patterns of Polymyositis With Mitochondrial Pathology and Inclusion Body Myositis. Neurology 2022; 99: e2212-e2222 DOI: 10.1212/WNL.0000000000201103.
• 75 Michelle EH, Mammen AL. Myositis Mimics. Curr Rheumatol Rep 2015; 17: 63 DOI: 10.1007/s11926-015-0541-0.
• 76 Cohen Aubart F, Abbara S, Maisonobe T. et al. Symptomatic muscular sarcoidosis: Lessons from a nationwide multicenter study. Neurol Neuroimmunol Neuroinflamm 2018; 5: e452 DOI: 10.1212/NXI.0000000000000452.
• 77 Suresh SC, Hasan A, Zonnoor SL. et al. Can IgG4-related disease present as isolated myositis?. Neuromuscul Disord 2023; 33: 570-574 DOI: 10.1016/j.nmd.2023.04.004.
• 78 Ruffer N, Krusche M, Holzer M-T. et al. Differenzialdiagnose eines vaskulitischen Syndroms der unteren Extremität. Z Rheumatol 2022; 81: 871-880 DOI: 10.1007/s00393-021-01044-w.
• 79 Mammen AL. Toxic myopathies. Continuum (Minneap Minn) 2013; 19: 1634-1649 DOI: 10.1212/01.CON.0000440663.26427.f4.
• 80 Crum-Cianflone NF. Infection and musculoskeletal conditions: Infectious myositis. Best Pract Res Clin Rheumatol 2006; 20: 1083-1097 DOI: 10.1016/j.berh.2006.08.005.
• 81 Halilu F, Christopher-Stine L. Myositis-specific Antibodies: Overview and Clinical Utilization. Rheumatol Immunol Res 2022; 3: 1-10 DOI: 10.2478/rir-2022-0001.
• 82 Oldroyd AGS, Lilleker JB, Amin T. et al. British Society for Rheumatology guideline on management of paediatric, adolescent and adult patients with idiopathic inflammatory myopathy. Rheumatology (Oxford) 2022; 61: 1760-1768 DOI: 10.1093/rheumatology/keac115.
• 83 Aggarwal R, Charles-Schoeman C, Schessl J. et al. Trial of Intravenous Immune Globulin in Dermatomyositis. N Engl J Med 2022; 387: 1264-1278 DOI: 10.1056/NEJMoa2117912.
• 84 Aggarwal R, Schessl J, Charles-Schoeman C. et al. Safety and tolerability of intravenous immunoglobulin in patients with active dermatomyositis: results from the randomised, placebo-controlled ProDERM study. Arthritis Res Ther 2024; 26: 27 DOI: 10.1186/s13075-023-03232-2.
• 85 Casal-Dominguez M, Pinal-Fernandez I, Mammen AL. Inhibiting interferon pathways in dermatomyositis: rationale and preliminary evidence. Curr Treatm Opt Rheumatol 2021; 7: 258-271 DOI: 10.1007/s40674-021-00182-1.
• 86 Paik JJ, Casciola-Rosen L, Shin JY. et al. Study of Tofacitinib in Refractory Dermatomyositis: An Open-Label Pilot Study of Ten Patients. Arthritis Rheumatol 2021; 73: 858-865 DOI: 10.1002/art.41602.
• 87 Saygin D, Werth V, Paik JJ. et al. Current myositis clinical trials and tribulations. Ann Rheum Dis 2024; DOI: 10.1136/ard-2023-224652.
• 88 Alexanderson H. Exercise in Myositis. Curr Treatm Opt Rheumatol 2018; 4: 289-298 DOI: 10.1007/s40674-018-0113-3.
• 89 Corrado B, Ciardi G, Lucignano L. Supervised Physical Therapy and Polymyositis/Dermatomyositis-A Systematic Review of the Literature. Neurol Int 2020; 12: 77-88 DOI: 10.3390/neurolint12030015.
• 90 Munters LA, Loell I, Ossipova E. et al. Endurance Exercise Improves Molecular Pathways of Aerobic Metabolism in Patients With Myositis. Arthritis Rheumatol 2016; 68: 1738-1750 DOI: 10.1002/art.39624.
• 91 Liu L, Zhang Y, Liu S. et al. Compounded sulfamethoxazole improved the prognosis of dermatomyositis patients positive with anti-melanoma differentiation-associated gene 5. Rheumatology (Oxford) 2023; 62: 3095-3100 DOI: 10.1093/rheumatology/kead034.
• 92 Campar A, Alves I, Da Silva AM. et al. Idiopathic inflammatory myopathies - The burden of disease: Cohort analysis focusing on damage and comorbidities. Autoimmun Rev 2023; 22: 103455 DOI: 10.1016/j.autrev.2023.103455.